Rex, John H.

Empirical Fluconazole versus Placebo for Intensive Care Unit Patients: A Randomized Trial

Schuster, M. G., Edwards, J. E., Sobel, J. D., Darouiche, R. O., Karchmer, A. W., Hadley, S., Slotman, G., Panzer, H., Biswas, P., & Rex, J. H. (2008) · Annals of Internal Medicine

Antifungal resistance and susceptibilityNosocomial Infections in ICU

Cited by 210

Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: enhanced ability to detect amphotericin B-resistant Candida isolates

Wanger, A., Mills, K., Nelson, P. W., & Rex, J. H. (1995) · Antimicrobial Agents and Chemotherapy

Antifungal resistance and susceptibilityBacterial Identification and Susceptibility Testing

Cited by 202

Detection of amphotericin B-resistant Candida isolates in a broth-based system

Rex, J. H., Cooper, C. R., Merz, W. G., Galgiani, J. N., & Anaissie, E. J. (1995) · Antimicrobial Agents and Chemotherapy

Antifungal resistance and susceptibilityFungal Plant Pathogen Control

Cited by 198

International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia

Ostrosky-Zeichner, L., Kontoyiannis, D., Raffalli, J., Mullane, K. M., Vazquez, J., Anaissie, E. J., Lipton, J., Jacobs, P., Rensburg, J. H. J., Rex, J. H., et al. (2005) · European Journal of Clinical Microbiology & Infectious Diseases

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 189

Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: approach to developing practical criteria for systematic use in antifungal prophylaxis trials

Paphitou, N. I., Ostrosky-Zeichner, L., & Rex, J. H. (2005) · Medical Mycology

Antifungal resistance and susceptibilityNosocomial Infections in ICU

Cited by 179

Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution.

Pfaller, M. A., Espinel-Ingroff, A., Canton, E., Castanheira, M., Cuenca-Estrella, M., Diekema, D. J., Fothergill, A., Fuller, J., Ghannoum, M., Jones, R. N., et al. (2012) · Journal of Clinical Microbiology

Antifungal resistance and susceptibilityYeasts and Rust Fungi Studies

Cited by 174

Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis

Rex, J. H., Nelson, P. W., Paetznick, V. L., Lozano-Chiu, M., Espinel-Ingroff, A., & Anaissie, E. J. (1998) · Antimicrobial Agents and Chemotherapy

Antifungal resistance and susceptibilityBacterial Identification and Susceptibility Testing

Cited by 167

Prophylactic antifungal therapy in the intensive care unit

Weinstein, R. A., Rex, J. H., & Sobel, J. D. (2001) · Clinical Infectious Diseases

Antifungal resistance and susceptibilityNosocomial Infections in ICU

Cited by 155

The Trailing End Point Phenotype in Antifungal Susceptibility Testing Is pH Dependent

Marr, K. A., Rustad, T. R., Rex, J. H., & White, T. C. (1999) · Antimicrobial Agents and Chemotherapy

Antifungal resistance and susceptibilityBacterial Identification and Susceptibility Testing

Cited by 145

Risk Factors and Predictors of Outcome in Patients with Cancer and Breakthrough Candidemia

Uzun, O., Ascioglu, S., Anaissie, E. J., & Rex, J. H. (2001) · Clinical Infectious Diseases

Antifungal resistance and susceptibilityNeutropenia and Cancer Infections

Cited by 138

Invasive candidiasis in immunocompromised hospitalized patients.

Sims, C. R., Ostrosky-Zeichner, L., & Rex, J. H. (2005) · Archives of Medical Research

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 124

Declining Rates of Oropharyngeal Candidiasis and Carriage of Candida albicans Associated with Trends Toward Reduced Rates of Carriage of Fluconazole‐Resistant C. albicans in Human Immunodeficiency Virus –Infected Patients

Martins, M. D., Lozano‐Chiu, M., & Rex, J. H. (1998) · Clinical Infectious Diseases

Antifungal resistance and susceptibilityHIV/AIDS oral health manifestations

Cited by 103

The Orotomide Olorofim Is Efficacious in an Experimental Model of Central Nervous System Coccidioidomycosis

Wiederhold, N. P., Najvar, L. K., Jaramillo, R., Olivo, M., Birch, M., Law, D., Rex, J. H., Catano, G., & Patterson, T. F. (2018) · Antimicrobial Agents and Chemotherapy

Fungal Infections and StudiesAntifungal resistance and susceptibility

Cited by 80

Efficacy of Olorofim (F901318) against Aspergillus fumigatus , A. nidulans , and A. tanneri in Murine Models of Profound Neutropenia and Chronic Granulomatous Disease

Seyedmousavi, S., Chang, Y. C., Law, D., Birch, M., Rex, J. H., & Kwon-Chung, K. J. (2019) · Antimicrobial Agents and Chemotherapy

Antifungal resistance and susceptibilityFungal and yeast genetics research

Cited by 56

Point Prevalence of Oropharyngeal Carriage of Fluconazole‐Resistant Candida in Human Immunodeficiency Virus–Infected Patients

Martins, M. D., Lozano‐Chiu, M., & Rex, J. H. (1997) · Clinical Infectious Diseases

Antifungal resistance and susceptibilityHIV/AIDS oral health manifestations

Cited by 54